Synmosa Biopharma has set a new bar for itself. The company reported NT$5.84 billion in consolidated revenue for the first three quarters of the year, topping all its past results. In the third quarter alone, revenue jumped 49.19% year-over-year to NT$2.293 billion. This surge came as Synmosa rolled out new products and caught the annual spike in demand for respiratory and allergy drugs during the colder months.
United Daily News, citing independent reporting, put Synmosa's consolidated revenue for September 2026 at about NT$740 million. That marks a 38.6–39% increase from the same month last year. Synmosa pointed to strong autumn-winter demand and the lift from new product launches as the main drivers. Some reports mention an NT$750 million figure for September, but that number still needs to be checked against official filings from the company or the Taiwan Stock Exchange.
In October 2026, Synfanas—a combination nasal spray developed and produced by Synmosa's subsidiary Intech Biopharm—officially entered the Taiwanese market after securing regulatory approval and National Health Insurance pricing.
September's NT$750 million tally, up 39% year-over-year, set a new monthly record for Synmosa, even though it dipped slightly from August. The company didn't rely on a single blockbuster. Instead, it saw gains across its main therapeutic areas. Oncology drug sales climbed 41% from last year. Cardiovascular and metabolic products shot up 48%. Women's health care rose 25%. The cardiovascular and metabolic segment got a big boost after Synmosa picked up Taiwan distribution rights for four major international hypertension drugs and a leading anticoagulant brand, which helped ramp up revenue in that category.
Respiratory and women's health drive expansion
Synmosa's respiratory drugs are seeing more use in clinics, thanks in part to updated ARIA guidelines that now recommend combination therapy for allergic rhinitis. The company's main combination nasal sprays are in high demand. October brought the official launch of Synfanas, a new combination nasal spray from Intech Biopharm, Synmosa's subsidiary. With Taiwan drug approval and National Health Insurance pricing in place, Synfanas is now available to doctors, adding muscle to Synmosa's respiratory lineup as cold season picks up. United Daily News reports that Synfanas should help the respiratory segment by building on the effects of existing products, reaching more of the market, and taking advantage of seasonal demand. However, Synfanas sales numbers have not yet been released.
In women's health, Synmosa's broad approach is paying off. Its new oral GnRH antagonist for uterine fibroids, launched earlier this year, has already reached 130 medical institutions, including 12 top medical centers. The company has worked closely with the medical community, including at the Taiwanese Menopause Society annual meeting, which has helped deepen clinical ties and drive adoption of its women's health products.
Independent publications confirm that Synmosa's reported September revenue growth of about 39% is accurate, but the precise figure of NT$750 million cited in some reports differs from the NT$740 million stated in United Daily News, highlighting the need for verification through official company disclosures or the Taiwan Stock Exchange.
Digestive disease and new product penetration
The digestive disease segment is also picking up steam. Synmosa's new chronic constipation drug, launched in March, is now stocked in over 220 medical institutions, including seven medical centers. At Taiwan Digestive Disease Week, the company gathered feedback from more than 100 doctors, showing strong clinical interest and demand for this new treatment.
Market analysts say the nearly 50% year-over-year revenue growth in the third quarter came from a mix of new cardiovascular distribution rights, seasonal demand for respiratory drugs, and the steady rollout of new products in women's health and digestive diseases. This kind of diversification echoes recent industry moves, like the reported acquisition of respiratory assets by Zymeworks.
Strategic outlook
Synmosa is pushing ahead, aiming for deeper market reach as its new products gain ground in clinics and hospitals. The fourth quarter, usually the busiest for respiratory drugs, stands to benefit from the official Synfanas launch and the growing presence of its uterine fibroid and chronic constipation treatments. Synmosa's two-pronged strategy—acquiring distribution rights for international originator drugs while developing its own new products—has helped it move beyond generics into high-value, specialized areas. This focus and willingness to invest in both established and innovative drugs have made Synmosa a strong player in the region. The numbers back it up: Synmosa has not only handled the ups and downs of the sector but has used them to build a platform for steady, multi-segment growth.
